Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.11 USD | +1.83% | +1.82% | +103.64% |
19/04 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
01/04 | Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Sales 2024 * | 7.5M 626M | Sales 2025 * | 18.75M 1.56B | Capitalization | 40.23M 3.36B |
---|---|---|---|---|---|
Net income 2024 * | -67M -5.59B | Net income 2025 * | -72M -6.01B | EV / Sales 2024 * | -20.8 x |
Net cash position 2024 * | 196M 16.37B | Net cash position 2025 * | 302M 25.16B | EV / Sales 2025 * | -13.9 x |
P/E ratio 2024 * |
-0.67
x | P/E ratio 2025 * |
-0.9
x | Employees | 73 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.09% |
Latest transcript on Xilio Therapeutics, Inc.
1 day | +2.75% | ||
1 week | +1.82% | ||
Current month | +3.70% | ||
1 month | -26.80% | ||
3 months | +67.41% | ||
6 months | -46.67% | ||
Current year | +103.64% |
Managers | Title | Age | Since |
---|---|---|---|
René Russo
CEO | Chief Executive Officer | 49 | 22/19/22 |
Kevin Brennan
DFI | Director of Finance/CFO | 54 | - |
Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Clancy
CHM | Chairman | 62 | 23/20/23 |
Daniel Curran
BRD | Director/Board Member | 57 | 01/20/01 |
Tomas Jan Heyman
BRD | Director/Board Member | 68 | 15/22/15 |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 1.11 | +1.83% | 28 432 |
26/24/26 | 1.09 | +7.92% | 144,163 |
25/24/25 | 1.01 | -4.72% | 239,428 |
24/24/24 | 1.06 | +0.95% | 297,031 |
23/24/23 | 1.05 | -4.55% | 448,445 |
Delayed Quote Nasdaq, April 29, 2024 at 07:37 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+103.64% | 40.23M | |
+2.07% | 42.75B | |
+47.81% | 41.61B | |
+12.18% | 41.34B | |
-12.36% | 26.59B | |
+8.03% | 25.49B | |
-23.72% | 18.12B | |
+30.13% | 12.24B | |
-1.78% | 11.76B | |
+7.89% | 11B |
- Stock Market
- Equities
- XLO Stock